Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P51681

UPID:
CCR5_HUMAN

ALTERNATIVE NAMES:
CHEMR13; HIV-1 fusion coreceptor

ALTERNATIVE UPACC:
P51681; O14692; O14693; O14695; O14696; O14697; O14698; O14699; O14700; O14701; O14702; O14703; O14704; O14705; O14706; O14707; O14708; O15538; Q9UPA4

BACKGROUND:
The protein C-C chemokine receptor type 5, known alternatively as CHEMR13 or HIV-1 fusion coreceptor, is integral in the immune response to inflammation and infection. It acts by transducing signals from CC-chemokines, leading to increased calcium ion levels intracellularly and playing a role in the migration of T-lymphocytes to sites of infection.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of C-C chemokine receptor type 5 could open doors to potential therapeutic strategies, particularly in the context of Type 1 diabetes mellitus 22 and HIV-1 infection. Its function as a chemotactic receptor and HIV-1 coreceptor presents unique opportunities for drug discovery and development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.